Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAdHIVNE1 Vaccine in Adults With and Without HIV
NCT06617091Phase 1Recruiting
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Jul 2025
- Primary completion
- Mar 2027
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of GRAdHIVNE1 in human immunodeficiency virus infection (HIV), sponsored by International AIDS Vaccine Initiative. Primary endpoint: Safety and tolerability of GRAdHIVNE1 vaccine at 7 days. Started Jul 2025; status: recruiting.
02
Drugs
GRAdHIVNE1
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06617091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617091.